Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) will likely be issuing its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.07) per share and revenue of $49.0610 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 5:00 PM ET.

Maravai LifeSciences Stock Up 0.6%

Shares of Maravai LifeSciences stock opened at $3.10 on Monday. Maravai LifeSciences has a one year low of $1.66 and a one year high of $4.30. The company has a market cap of $792.70 million, a P/E ratio of -3.69 and a beta of 0.39. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.56 and a current ratio of 5.29. The firm has a fifty day moving average of $3.46 and a two-hundred day moving average of $3.18.

Insiders Place Their Bets

In other Maravai LifeSciences news, Director Gregory T. Lucier bought 51,472 shares of the business’s stock in a transaction on Friday, December 5th. The stock was bought at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the completion of the transaction, the director owned 106,595 shares in the company, valued at approximately $394,401.50. The trade was a 93.38% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.11% of the company’s stock.

Institutional Investors Weigh In On Maravai LifeSciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new stake in Maravai LifeSciences during the 4th quarter valued at $7,670,000. Millennium Management LLC boosted its stake in shares of Maravai LifeSciences by 308.7% during the fourth quarter. Millennium Management LLC now owns 1,797,052 shares of the company’s stock valued at $5,840,000 after acquiring an additional 1,357,349 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Maravai LifeSciences by 52.3% during the fourth quarter. Marshall Wace LLP now owns 2,000,278 shares of the company’s stock valued at $6,501,000 after acquiring an additional 687,253 shares during the last quarter. Cerity Partners LLC purchased a new stake in Maravai LifeSciences during the 4th quarter worth about $1,521,000. Finally, Goldman Sachs Group Inc. raised its stake in Maravai LifeSciences by 28.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,014,214 shares of the company’s stock valued at $6,546,000 after purchasing an additional 442,059 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company raised their price objective on shares of Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research report on Monday, December 15th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $5.25.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.